20258-98-4

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dihydroxy-naphthalene-1-carbaldehyde is used as a key intermediate for the synthesis of complex molecules with potential biological and pharmacological activities. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Dyes Industry:
2,6-Dihydroxy-naphthalene-1-carbaldehyde is used as a building block for the synthesis of various dyes. Its unique structure allows for the creation of dyes with specific properties, making it a valuable resource in the dyes industry.
Used in Materials Industry:
2,6-Dihydroxy-naphthalene-1-carbaldehyde is used in the development of new materials due to its unique structure and reactivity. Its potential applications in this industry include the creation of materials with specific properties for various uses.
Used in Antioxidant and Anti-Inflammatory Applications:
2,6-Dihydroxy-naphthalene-1-carbaldehyde has been investigated for its antioxidant and anti-inflammatory properties, making it a potential candidate for use in applications that require these characteristics, such as in the development of health supplements or in the treatment of inflammatory conditions.

Upstream product

• 581-43-1 2.6-dihydroxynaphthalene 
• 74-90-8 hydrogen cyanide 
• 20258-97-3 1-[(phenylimino)methyl]naphthalene-2,6-diol 
• 3473-63-0 formamidine acetic acid 
• 1092649-44-9 2,6-bis(methoxymethoxy)naphthalene 
• 68-12-2 N,N-dimethyl-formamide 

Relevant academic research and scientific papers

Construction of Highly Functionalized Xanthones via Rh-Catalyzed Cascade C-H Activation/ O-Annulation

A facile and efficient strategy for obtaining functionalized and multihydroxylated xanthones via Rh catalysis under redox-neutral conditions is developed. Diverse salicylaldehydes bearing heterocycles, aromatics, and fused aromatics can be rapidly coupled with 1,4-benzoquinones or 1,4-hydroquinones to afford valuable xanthones via cascade C-H/O-H functionalization and annulation. This protocol provides a rapid synthetic approach to obtain biologically active materials through late-stage functionalization and prepares natural products such as subelliptenone, pruniflorone N, and ravenelin.

SMALL MOLECULE INHIBITORS OF A PROTEIN COMPLEX

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease

A novel series of boron-containing compounds were designed, synthesized and evaluated as multi-target-directed ligands against Alzheimer's disease. The biological activity results demonstrated that these compounds possessed a significant ability to inhibit self-induced Aβ aggregation (20.5-82.8%, 20 μM) and to act as potential antioxidants (oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values of 2.70-5.87). In particular, compound 17h is a potential lead compound for AD therapy (IC50 = 3.41 μM for self-induced Aβ aggregation; ORAC-FL value = 4.55). Compound 17h also functions as a metal chelator. These results indicated that boron-containing compounds could be new structural scaffolds for the treatment of AD.

Benzo-hexatomic ring derivative used as DPP-4 inhibitor and application of benzo-hexatomic ring derivative

The invention relates to a benzo-hexatomic ring derivative used as a DPP-4 inhibitor and application of the benzo-hexatomic ring derivative, in particular to compounds shown as in formula I, medicine compositions with the compounds shown as in the formula I and application of the compounds in preparing medicines for treating diseases related to DPP-4 or inhibiting the DPP-4.

Experimental and theoretical studies on constitutional isomers of 2, 6-dihydroxynaphthalene carbaldehydes. effects of resonance-assisted hydrogen bonding on the electronic absorption spectra

We prepared and characterized a series of mono-and dicarbaldehydes of 2, 6-dihydroxynaphthalene that bear potential resonance-assisted hydrogen bonding (RAHB) unit(s). X-ray crystal structures of selected compounds revealed that each salicylaldehyde moiety forms an intramolecular hydrogen bond and that the introduction of formyl groups into either the α-or β-position causes a considerable difference in geometry, which was interpretative from a conventional scheme of resonance hybrids including ionic state. Analyses on NMR chemical shifts suggested that the compounds in solution are present as an equilibrium mixture between closed and open forms with respect to RAHB units. Ab initio calculations indicated that the formation of an intramolecular hydrogen bond strikingly influences the aromaticity of the individual local six-membered ring of naphthalene. The trend of the change in aromaticity was analyzed in connection with the extra stabilization energy of RAHB. In the UV-vis spectra, the β-formyl derivatives specifically showed a substantial red shift compared to α-formyl derivatives. The absorption features were successfully reproduced by TD-DFT calculation, and those data were consistently explained from the effects of RAHB on electronic state of the naphthalene's π-system. Finally, we pointed out a similarity in the electronic state between RAHB-bearing molecules and cata-condensed aromatic hydrocarbons. Copyright 2009 by the American Chemical Society.

Selective irreversible inhibition of fructose 1,6-bisphosphate aldolase from Trypanosoma brucei

An irreversible competitive inhibitor hydroxynaphthaldehyde phosphate was synthesized that is highly selective against the glycolytic enzyme fructose 1,6-bisphosphate aldolase from Trypanosoma brucei (causative agent of sleeping sickness). Inhibition invo

Inhibitors of protein kinase for the treatment of disease

The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compounds and pharmaceutical compositions comprising these compounds.